Skip to content

PREhospital Routage of Acute STroke Patients With Suspected Large Vessel Occlusion: Mothership Versus Drip and Ship

PREhospital Routage of Acute STroke Patients With Suspected Large Vessel Occlusion: Mothership Versus Drip and Ship, a Randomized Control Study in France (PRESTO-F)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04121013
Acronym
PRESTO-F
Enrollment
800
Registered
2019-10-09
Start date
2021-01-30
Completion date
2022-01-31
Last updated
2021-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Keywords

thrombectomy, drip'n'ship versus mothership, cost/effectiveness

Brief summary

Background: The outcome of ischemic stroke is related to the brain lesion volume and this volume of infarction is directly related to the time to reperfusion, which therefore depends on the time to initiation of therapy. Acute ischemic stroke is treated medically with the administration of intravenous rtPA, but recent randomized controlled trials have shown the efficacy of mechanical thrombectomy and is now the new gold standard in ischemic stroke. This new therapeutic strategy has created two possibilities for pre-hospital decision-making: i/ transport the patient directly to the nearest stroke unit to receive alteplase and then if indicated perform a thrombectomy (drip and ship) or ii/ bypassing thrombolysis centres in favour of endovascular thrombectomy (mothership). Objective: To compare cost/effectiveness of transfer to the closest local stroke centre or telemedicine hub to direct transfer to the comprehensive stroke cent(CSC) in patients acute stroke with suspected large vessel occlusion. Medical and economic expected impact: We hypothesize that direct transportation to CSC is associated with better clinical outcome in case of acute ischaemic stroke due to intracranial large vessel occlusion. However, we have to demonstrate that this approach is not associated with time from onset harm in patients not eligible to mechanical thrombectomy.

Detailed description

Design: Multicenter, two-arm, prospective, open, blinded end-point (PROBE), randomized, clinical trial Primary endpoint: Incremental cost-utility ratio at 12 months. Secondary endpoints: modified Rankin scale and EuroQoL5D scale at 3 months. Eligibility criteria: A call to the emergency medical assistance service, 18 years and older, severe acute stroke symptoms, transportation time from scene to the CSC longer than time to go to the nearest stroke unit or telemedicine hub, transportation time from scene to the CSC compatible with IV thrombolysis, known time from onset, RACE score (assessed by medical emergency technicians) ≥5. Experimental arm: direct transportation to the CSC. Control arm: transfer to the closest local stroke centre or telemedicine hub. Sample size: 800 patients, 400 for each arm.

Interventions

OTHERmothership

Randomized controlled study: allocation to active or no intervention arm will be done accordingly to the design temporal sequence

Sponsors

University Hospital, Caen
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* A call to the emergency medical assistance service; * age\> 18y, * known time of stroke onset; * transportation time from scene to the CSC longer than time to go to the nearest stroke unit or telemedicine hub; * transportation time from scene to the CSC compatible with IV thrombolysis; * known time from onset, RACE score ≥5.

Exclusion criteria

* transportation time from scene to the CSC longer than time to go to the nearest stroke unit or telemedicine hub. * no ambulance available * bedridden patient

Design outcomes

Primary

MeasureTime frameDescription
Incremental cost-utility ratio12 monthsIncremental cost-utility ratio (ICUR) at 12 months, defined as the ratio of the incremental cost of management by transfer to a CSC with MT (compared to the control arm local PSC) to the gain in healthy survival (quality adjusted life years, QALYs).

Secondary

MeasureTime frameDescription
modified Rankin scale score90 daysis a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6, running from perfect health without symptoms to death. Modified Rankin Scale score will be evaluated through a structured telephone-based interview performed by a central assessor who is blinded to group assignment

Other

MeasureTime frameDescription
EuroQoL5D scale90 daysEQ-5D is a standardized instrument for measuring generic health status. In the description part, health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. EuroQol5D scale will be evaluated through a structured telephone-based interview performed by a central assessor who is blinded to group assignment

Countries

France

Contacts

Primary ContactRichard Macrez, Dr
macrez@cyceron.fr0231470213
Backup Contactemmanuel touze, Pr
emmanuel.touze@unicaen.fr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026